Life Sciences

  • June 23, 2026

    Green Group Wants Records Behind Trump's Weed Killer Order

    An environmental organization on Monday sued the U.S. Department of Agriculture in D.C. federal court, seeking records behind President Donald Trump's executive order to hike the production of glyphosate, the active ingredient in the weed killer Roundup, an allegedly carcinogenic pesticide at the center of an imminent U.S. Supreme Court decision.

  • June 23, 2026

    BioNTech Accused Of Firing Nurse Over Drug Trial Concerns

    A former senior clinical trial manager at BioNTech US Inc. told a North Carolina federal court Monday that she was wrongfully fired after complaining to higher-ups about an "epidemic of safety issues and protocol deviations" in clinical trials.

  • June 23, 2026

    Feds Tout AI's Role In $6.5B Healthcare Fraud Crackdown

    Federal authorities said Tuesday that artificial intelligence and sophisticated data analysis helped them detect and prosecute healthcare fraud as part of a national crackdown that resulted in charges against 455 defendants.

  • June 23, 2026

    Fed. Circ. Backs Pfizer Win In Paxlovid Patent Dispute

    The Federal Circuit on Tuesday refused to revive a patent that Pfizer was accused of infringing through its blockbuster Paxlovid COVID-19 treatment, rejecting the patent owner's arguments over what it said was a typo in a patent document.

  • June 23, 2026

    Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans

    Sangamo Therapeutics Inc. filed for bankruptcy protection in Delaware on Tuesday with offers to sell parts of its genetic therapy development programs to Eli Lilly and Co. and Astellas Pharma Inc.

  • June 22, 2026

    Can Unread Emails Trigger Arbitration? 9th Circ. Airs Doubts

    Medical supplies giant Thermo Fisher Scientific pressed a Ninth Circuit panel Monday to agree that the company's repeated emails about litigation waivers should send an ex-employee's proposed class action to arbitration, but the judges repeatedly questioned why no one simply asked if the worker saw the emails.

  • June 22, 2026

    Cassava Investors Ink $31M Drug Suit Deal Alongside Appeal

    Cassava Sciences investors have asked a Texas federal judge to preliminarily approve a $31 million settlement that ends their claims the pharmaceutical company inflated its stock prices with misleading information about its Alzheimer's drug research, a deal that could be upended if the court's class certification order is reversed on appeal.

  • June 22, 2026

    Zymergen Investors Get First OK For $125M Settlement

    Former executives, underwriters and large investors of now-defunct biotechnology company Zymergen received initial approval on Monday of a $125 million deal to end claims that they misled shareholders ahead of the company's initial public offering by approving misstatements about Zymergen's commercial product pipeline.

  • June 22, 2026

    FTC Requires Fix For Aurobindo's $250M Lannett Deal

    The Federal Trade Commission is allowing Aurobindo Pharma Ltd. to move ahead with its planned $250 million acquisition of Lannett Co. Inc., after the pharmaceutical company agreed to unload four generic drug products to prevent potential overlaps.

  • June 22, 2026

    No Trial For Splenda Maker, Scientist In Defamation Suit

    Splenda maker TC Heartland LLC and the scientist whom it accused of defamation were sent packing from North Carolina federal court Monday, after a judge found neither had offered evidence to overcome the other's First Amendment right to talk about scientific research.

  • June 22, 2026

    Sorrento RICO Case Naming Jackson Walker Gets Axed

    A Texas bankruptcy judge blocked a lawsuit in California federal court alleging Jackson Walker LLP and executives at Sorrento Therapeutics and M3 Partners conspired to forum shop in Texas so the drug developer could seek Chapter 11 protection in an "ethically compromised" bankruptcy court, ruling the suit's claims are barred by Sorrento's bankruptcy plan.

  • June 22, 2026

    NORML Fights Exclusion From DEA Pot Rescheduling Hearing

    The National Organization for the Reform of Marijuana Laws, a leading cannabis consumer advocate, has asked the U.S. Drug Enforcement Administration to reconsider its move freezing out all pro-reform voices from upcoming hearings on a proposal to reschedule marijuana.

  • June 22, 2026

    Yale Health Escapes Trade Law Claim In Insemination Suit

    Yale New Haven Health Services Corp. has defeated Connecticut trade law, emotional distress and informed consent claims in a lawsuit accusing a doctor of fraudulently using his own sperm to inseminate a fertility patient, but the hospital network holding entity must face a fraud allegation, a state judge has ruled.

  • June 22, 2026

    3rd Circ. Backs Quest Over Claims Of Bad 401(k) Management

    The Third Circuit on Monday affirmed Quest Diagnostics Inc.'s victory over a proposed class action accusing the company of mismanaging its employee 401(k) plan, holding the company followed a prudent process in deciding to retain two challenged investment funds despite periods of underperformance.

  • June 22, 2026

    Holland & Knight Adds Jones Day Atty To Atlanta, DC Teams

    Holland & Knight LLP has bolstered its ranks in Atlanta and Washington, D.C., by adding an attorney from Jones Day with experience helping clients navigate investigations brought by enforcers including the U.S. Department of Justice and the U.S. Securities and Exchange Commission. 

  • June 22, 2026

    USTR Launches Probe Into German Pharma Costs

    The U.S. Trade Representative has opened an investigation into whether Germany has been underpaying for certain pharmaceutical products in a way that burdens U.S. consumers with added costs, which could lead to added tariffs.

  • June 22, 2026

    Gov't Says It Should Face Vax IP Claims, Not Moderna

    The U.S. Department of Justice has told the Federal Circuit that multibillion-dollar patent infringement litigation should be directed at the government, instead of Moderna, for the drugmaker's development and supply of COVID vaccines during the pandemic.

  • June 22, 2026

    Justices Seek Solicitor General's Views On Drug Pricing Law

    The U.S. Supreme Court on Monday asked the federal government to weigh in on whether it should hear the pharmaceutical industry's challenge to Oregon's drug pricing transparency law, which drugmakers say forces them to justify pricing decisions and risks exposing trade secrets.

  • June 22, 2026

    Paul Weiss, Kirkland Steer $10.9B AbbVie, Apogee Deal

    AbbVie said Monday it has agreed to buy Apogee Therapeutics, a company developing therapies for inflammatory and immunological diseases, at a total equity value of approximately $10.9 billion, with Paul Weiss Rifkind Wharton & Garrison LLP and Kirkland & Ellis LLP advising. 

  • June 18, 2026

    Eli Lilly Weight Drug TM Deal Too Secretive, Ind. Judge Says

    An Indiana federal judge on Thursday refused to sign off on a confidential settlement that would bar a telehealth company from selling knock-offs of Eli Lilly's weight-loss medications, saying the companies didn't provide enough information for him to consider the deal.

  • June 18, 2026

    Express Scripts Can't Ditch Meta Wiretap Suit Yet

    A California federal judge refused to dismiss a proposed class action alleging Express Scripts lets Meta secretly read consumers' communications, saying a consumer sufficiently claimed the online pharmacy allowed Meta's unauthorized collection of personal health information.

  • June 18, 2026

    Fertility Chain Beats Suit Alleging Bogus Embryo Test Claims

    A fertility clinic chain has defeated a proposed class action accusing it of deceptively marketing its preimplantation genetic testing, after a Colorado federal judge found none of the patients claimed their own tests were inaccurate or caused a miscarriage or failed pregnancy.

  • June 18, 2026

    Novo Nordisk Sued Over Data Hack Tied To Extortionist Group

    Novo Nordisk was hit with a proposed negligence class action in New Jersey federal court alleging the pharmaceutical giant failed to have adequate data security measures in place to protect sensitive personal health information of patients and employees from being exposed to a cybercriminal extortionist group.

  • June 18, 2026

    Once Dominated By Patent Claims, IP Suits Now More Diverse

    Intellectual property litigation has become more spread out among patents, trademarks and copyrights over the years, as artificial intelligence and e-commerce systems have been drivers of legal matters, according to a new report.

  • June 18, 2026

    Full Fed. Circ. Skips DePuy Bid To Redo Spine Patent Dispute

    The full Federal Circuit won't revisit a panel decision that gave new life to an inventor's suit accusing DePuy Synthes Cos. of infringing his spinal realignment method patents, letting stand the decision that faulted a lower court's handling of expert testimony in the case.

Expert Analysis

  • Series

    Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief

    Author Photo

    My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.

  • 5 Drug Pricing Policy Developments To Watch In 2026

    Author Photo

    2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.

  • Patent Applicants Must Get Biologics Enablement Right

    Author Photo

    As artificial intelligence increasingly becomes a core driver in drug discovery, it is critical for drug companies to adapt their drafting strategies to the unique features of AI-generated inventions, and to pay particularly close attention to enablement standards, says Sanandan Malhotra at Novo Nordisk.

  • Series

    Law School's Missed Lessons: How To Start A Law Firm

    Author Photo

    Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.

  • Fed. Circ. Patent Decisions In 2025: An Empirical Review

    Author Photo

    In 2025, the Federal Circuit's increased output was not enough to keep up with its ever-growing patent case load, and patent owners and applicants fared poorly overall as the court's affirmance rate fell, says Dan Bagatell at Perkins Coie.

  • Regulatory Uncertainty Ahead For Organ Transplant System

    Author Photo

    Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.

  • Key False Claims Act Trends From The Last Year

    Author Photo

    The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.

  • Opinion

    It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs

    Author Photo

    The U.S. Food and Drug Administration's decision this month to order removal of warnings about the risk of suicidal thoughts from GLP-1 weight-loss drugs is premature — and from a safety and legal standpoint, the downside of acting too soon could be profound, says Sean Domnick at Rafferty Domnick.

  • Series

    Hosting Exchange Students Makes Me A Better Lawyer

    Author Photo

    Opening my home to foreign exchange students makes me a better lawyer not just because prioritizing visiting high schoolers forces me to hone my organization and time management skills but also because sharing the study-abroad experience with newcomers and locals reconnects me to my community, says Alison Lippa at Nicolaides Fink.

  • FDA's 2025 Enforcement Scorecard Highlights Data Focus

    Author Photo

    The U.S. Food and Drug Administration's increased enforcement activity in 2025 was driven by artificial intelligence and a focus on foreign manufacturers, necessitating proactive compliance strategies for an environment that is increasingly reliant on data, say attorneys at Reed Smith.

  • How A 1947 Tugboat Ruling May Shape Work Product In AI Era

    Author Photo

    Rapid advances in generative artificial intelligence test work-product principles first articulated in the U.S. Supreme Court’s nearly 80-year-old Hickman v. Taylor decision, as courts and ethics bodies confront whether disclosure of attorneys’ AI prompts and outputs would reveal their thought processes, say Larry Silver and Sasha Burton at Langsam Stevens.

  • Navigating Privilege Law Patchwork In Dual-Purpose Comms

    Author Photo

    Three years after the U.S. Supreme Court declined to resolve a circuit split in In re: Grand Jury, federal courts remain split as to when attorney-client privilege applies to dual-purpose legal and business communications, and understanding the fragmented landscape is essential for managing risks, say attorneys at Covington.

  • How AI Drafting Should Transform Patent Filing Strategies

    Author Photo

    As agentic artificial intelligence reduces the time and expense required to draft and file patents, companies should shift focus away from rationing drafting hours and more toward governing optionality, says Ian Schick at Paximal.

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.